srch

IR contact. Renate Birkeli. Investor Relations ... An online presentation by Targovax's management to investors, analysts and the press will take place at ...

07.03.2022 · Email: erik.wiklund@targovax.com. Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com. Media enquiries: Andreas Tinglum - Corporate Communications (Norway) Phone: +47 9300 1773 Email: andreas.tinglum@corpcom.no . About Targovax. Activating the patient's immune system to fight cancer

07.03.2022 · Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media enquiries: Andreas Tinglum - Corporate Communications (Norway) Phone: +47 9300 1773 Email: andreas ...

Mar 07, 2022 · Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax's focus is to activate the patient's immune system to...

Webcast presentation on Xtrainvestor ... For a company presentation in Norwegian, please see video below. ... Targovax is a clinical stage immuno-oncology company ...

28.02.2022 · In Targovax, Dr. Gaal's core responsibilities will be to oversee all financial, investor relations and business development activities, as well as playing an integral role in defining and ...

Mar 07, 2022 · Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials. IR Contact Renate Birkeli Investor Relations renate.birkeli@targovax.com

07.03.2022 · The parties have entered into a collaboration agreement to develop Targovax´s TG mutant KRAS cancer vaccines in combination with Agenus´s ...

Report, Presentation, Webcast, ESEF, ESEF (view XBRL). March 9, 2022 Annual Report 2021. February 17, 2022 Q4 Fourth Quarter 2021.

Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media enquires: Andreas Tinglum - Corporate Communications (Norway) Phone: +47 9300 1773 Email: andreas.tinglum@corpcom.no About Targovax Activating the patient's immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage immuno-oncology ...

May 21, 2021 · May. 21, 2021, 01:19 AM. OSLO, Norway, May 21, 2021 /PRNewswire/ -- Targovax ASA, today announces that members of its executive management team is invited to present at upcoming conferences. ABGSC ...

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors.

Company presentation January · Capital markets day 2021. CAPITAL MARKETS DAY With strong clinical data generated on ONCOS-102, Targovax is moving into ...

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying its multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax's

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune ... Investor Relations. renate.birkeli@targovax.com ...

Investor, Number of Shares, % of top 20, % of total, Type, Country. Avanza Bank AB, 16 693 889, 19,73%, 8,86%, NOM, SWE.

Prospectus for the listing on Oslo Axess can be downloaded here (Subscription period expired 8. August 2016 at 16:00 hours CET). IR contact ...

Mar 14, 2022 · Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives.

May 21, 2021 · Targovax ASA is about to announce its earnings — here's what Wall Street expects Markets Insider Automation 187d Targovax to present at upcoming investor and scientific conferences

07.03.2022 · Investors & Media. Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene ...

14.03.2022 · The drop-down demerger is expected to be completed during June 2022, subject to the approval by the Annual General Meeting. For further information, please contact: Erik Digman Wiklund, CEO. Phone: +47 413 33 536. Email: erik.wiklund@targovax.com. Renate Birkeli, Investor Relations. Phone: +47 922 61 624. Email: renate.birkeli@targovax.com.

Investors & Media. Renate Birkeli. Investor Relations. renate.birkeli@targovax.com. Telephone: +47 922 61 624. Share. PRINT; STAY CONNECTED.

Nov 04, 2021 · Targovax's CEO will give an online presentation and update on the clinical program to investors, analysts and the press at 10:00 CET today (details below). ... Investor Relations Phone: +47 922 61 ...

On 9 March 2022, the Board of Directors of Targovax ASA approved the Company's Annual Report, including the financial statements for 2021, ...